Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116406 | 0.94 | GNAI3 (0.39) | GNAO1GNAI3GNAI1HRH1SIGMAR1 | |
| SCHEMBL2603219 | 0.86 | SLC18A3 (0.43) | GNAO1GNAI3GNAI1HRH1 | |
| SCHEMBL26494066 | 0.86 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19604917 | 0.84 | GNAO1 (0.58) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL15837589 | 0.83 | GBA1 (0.36) | GNAO1GNAI3GNAI1HRH1 | |
| SCHEMBL2116367 | 0.83 | GBA1 (0.36) | GNAO1GNAI3GNAI1HRH1 | |
| SCHEMBL24356351 | 0.82 | GNAO1 (0.61) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19604919 | 0.82 | GNAO1 (0.61) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL1615678 | 0.82 | GNAO1 (0.50) | GNAO1GNAI3GNAI1 | |
| SCHEMBL25075207 | 0.81 | GNAI3 (0.38) | GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GNAO1 1637/4885GNAI3 2190/4885GNAI1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.